Business Context and Reporting Period
Company: OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.)
Filing Type: Form 10-K
Period Ended: December 31, 2009
Business Overview: OncoGenex is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address treatment resistance. The company's pipeline includes five candidates: OGX-011 (lead candidate), OGX-427, OGX-225, SN2310, and CSP-9222. The company has no commercial products and has historically incurred losses.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Collaboration Revenue | $25.5 million | $0 |
| Total Operating Expenses | $28.1 million | $11.1 million |
| Net Loss | $5.5 million | $4.2 million |
| Cash, Cash Equivalents & Investments | $64.6 million | $12.4 million |
| Accumulated Deficit | ($53.5 million) | ($48.0 million) |
| Net Cash Provided by Operating Activities | $34.9 million | ($12.3 million) |
Note: The 2009 net loss includes a $3.0 million income tax expense related to withholding taxes on collaboration revenue and a $4.0 million charge related to excess facility lease liabilities.
Material Changes vs. Prior Period
- Revenue Recognition: The company recorded $25.5 million in collaboration revenue in Q4 2009, compared to zero revenue in 2008. This stems from a Collaboration Agreement with Teva Pharmaceutical Industries Ltd. for the development of OGX-011.
- Expense Increase: Operating expenses increased significantly to $28.1 million from $11.1 million in 2008. This was driven by higher R&D costs ($24.2 million vs. $7.8 million), including milestone payments to licensors (Isis and UBC) triggered by the Teva deal, and increased facility costs.
- Liquidity Improvement: Cash and investments surged from $12.4 million to $64.6 million, primarily due to a $50 million upfront payment from Teva and a $10 million equity investment from Teva.
- Restructuring Charges: The company recorded $4.0 million in charges related to the fair value of excess lease facility liabilities in 2009.
Guidance, Outlook, and Risks
Strategic Developments
- Teva Collaboration: In December 2009, OncoGenex entered a global collaboration with Teva for OGX-011. Teva paid $50 million upfront and will fund most Phase 3 trials. OncoGenex is obligated to contribute $30 million toward development (of which $3.5 million was spent in 2009).
- Clinical Pipeline:
- OGX-011: Three Phase 3 trials planned for 2010-2011 (Prostate Cancer and Non-Small Cell Lung Cancer). Phase 2 data showed survival benefits and pain palliation.
- OGX-427: Phase 1 trials ongoing; Phase 2 trial for prostate cancer expected to start mid-2010.
- SN2310: Phase 1 completed; company is exploring out-licensing options.
Outlook and Capital Resources
Management believes current capital resources ($64.6 million) are sufficient to fund operations into 2012, including the initiation and accrual of Phase 3 trials for OGX-011. The company expects to continue incurring losses as it advances its pipeline.
Risks and Contingencies
- Dependence on Teva: Success is heavily dependent on Teva's performance and commitment. Teva may terminate the agreement under certain conditions.
- Regulatory Risk: No products have received regulatory approval. Phase 3 trials may fail to demonstrate efficacy or safety.
- Lease Obligations: The company has a non-cancellable lease for excess office space in Bothell, WA, with a recorded liability of $4.6 million. Failure to sublease this space will result in continued cash outflows.
- Intellectual Property: The company relies on licenses from third parties (Isis, UBC, Bayer) and must pay royalties and milestones upon commercialization.
Key Facts for Investor Verification
- Revenue Sustainability: Verify the amortization schedule for the $25.5 million collaboration revenue and the timing of future milestone payments from Teva.
- Cash Burn Rate: Confirm the company's ability to fund the remaining $26.5 million of its $30 million development commitment to Teva without additional financing.
- Lease Liability: Assess the progress of subleasing the excess Bothell, WA facility to mitigate the $4.6 million liability and future cash outflows.
- Clinical Trial Initiation: Monitor the actual start dates of the three planned Phase 3 trials for OGX-011 (Q2/Q3 2010 and early 2011) as delays could impact cash runway.
- Licensor Obligations: Review the specific royalty and milestone payment triggers owed to Isis and UBC upon the achievement of Teva milestones.